CONTENT VALIDATION AND DISCLOSURES

Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process:

Dr D’Amico — No financial interests or affiliations to disclose. Dr Klotz — Consulting Fees: Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Merck and Company Inc, Sanofi-Aventis; Speakers Bureau: AstraZeneca Pharmaceuticals LP. Dr Merrick— No financial interests or affiliations to disclose. Dr Petrylak — Grants/Research Support and Speakers Bureau: Celgene Corporation, Eli Lilly and Company, Sanofi-Aventis; Consultant: Cell Genesys Inc, GPC Biotech Inc. Dr Roach — Grants/Research Support: Amgen Inc; Consulting Fees and Honorarium: Amgen Inc, AstraZeneca Pharmaceuticals LP, Calypso, Cytogen Corporation, MedImmune Inc, Praecis Pharmaceuticals Incorporated; Speakers Bureau: AstraZeneca Pharmaceuticals LP; Other Support: Siemens AG. Dr Swanson — No financial interests or affiliations to disclose.

---

The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest for themselves (or their spouses/partners) that have been resolved through a peer review process: Terry Ann Glauser, MD, MPH, Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Michelle Paley, MD, Margaret Peng, Lilliam Sklaver Poltorack, PharmD and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc. Research To Practice receives education grants from Abraxis Oncology, Amgen Inc, AstraZeneca Pharmaceuticals LP, Biogen Idec, Genentech BioOncology, Genomic Health Inc, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.